NCT00673361
Terminated
Phase 2
Phase II Pilot Trial of "Chemo-Switch" Regimen of Biochemotherapy Followed by Daily Low-Dose Temozolomide Plus Sorafenib in Advanced Melanoma
ConditionsMelanoma
Overview
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Duke University
- Enrollment
- 9
- Primary Endpoint
- Progression Free Survival (PFS)
Overview
Brief Summary
This research study is testing the "chemo-switch" strategy in melanoma, using biochemotherapy initially to shrink tumors and then switching to daily low-dose chemotherapy (temozolomide) together with sorafenib. The purpose of this study is to find out what effects (good and bad) biochemotherapy followed by temozolomide plus sorafenib have on melanoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must have histologically or cytologically confirmed melanoma that is locally advanced or metastatic. Cutaneous, mucosal, ocular, and unknown primary melanoma are all eligible.
- •Must have measurable disease, defined by RECIST as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>20mm with conventional techniques or \>10mm with spiral CT scan.
- •May have received prior radiation therapy to one or more non-index lesions (prior radiation to an index lesion is allowable only if progression of the irradiated lesion is demonstrated, with progression defined as an increase of 20% or more in the largest diameter) and/or one prior vaccine therapy for metastatic disease. Prior adjuvant therapy with IFN alpha-2b, vaccine, and/or granulocyte-macrophage colony-stimulating factor (GM-CSF) is permitted. At least 4 weks must have elapsed since the completion of any prior therapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Patients must have normal organ and marrow function as defined below:
- •leukocytes \>3,000/uL (microliters)
- •absolute neutrophil count \>1,500/uL
- •platelets \>100,000/uL
- •total bilirubin \<2.0mg/dL
- •AST (Aspartate transaminase)(SGOT)/ALT (Alanine transaminase)(SGPT) \<2.5 X institutional upper limit of normal
Exclusion Criteria
- •Prior chemotherapy, cytokine therapy (including IL-2 or IFN alpha), or antibody therapy for metastatic disease. Prior vaccine therapy is permitted.
- •May not be currently receiving any other antineoplastic treatments, including chemotherapy, biologic response modifiers, radiation, vaccine, or investigational agents.
- •History of brain metastases.
- •Autoimmune disorders that could result in life-threatening complications in the setting of IFN alpha and IL-2 treatment.
- •History of sensitivity to E. coli-derived products.
- •Concurrent use of corticosteroids or any medical condition likely to require the use of systemic corticosteroids.
- •A seizure disorder currently requiring anti-epileptic medication.
- •Uncontrolled intercurrent illness including, but not limited to, hypertension, active infection requiring antibiotic therapy, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Evidence of bleeding diathesis.
- •Currently on therapeutic anticoagulation. Prophylactic anticoagulation (such as low-dose warfarin) of venous or arterial access devices is allowed provided the PT, PTT (Partial Thromboplastin Time), and international normalized ratio (INR) are normal.
Arms & Interventions
"Chemo-Switch" Regimen
Experimental
Intervention: Concurrent decrescendo biochemotherapy regimen (Drug)
"Chemo-Switch" Regimen
Experimental
Intervention: Low-dose Temozolomide plus Sorafenib (Drug)
Outcomes
Primary Outcomes
Progression Free Survival (PFS)
Time Frame: 3 weeks, 6 weeks, 16 weeks, & 24 weeks
Terminated study before accrual goal, no data analysis
Secondary Outcomes
- Response Rate as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria(post-cycle 1 of low-dose temozolomide plus sorafenib, then every 3 months for up to 2 years)
Investigators
Similar Trials
Completed
Phase 2
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in VivoPatients at Risk for MelanomaNCT01612221University of Utah100
Terminated
Phase 2
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTIONMelanoma (Skin)Melanoma, Stage IINCT04901988The Christie NHS Foundation Trust8
Completed
Phase 2
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ AdenocarcinomaEsophageal CancerGastric CancerNCT00737438Memorial Sloan Kettering Cancer Center22
Terminated
Phase 2
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast CancerBreast NeoplasmsMalignant Tumor of the BreastNCT02229149US Oncology Research33
Not yet recruiting
Phase 1
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial CancerOvarian NeoplasmsEndometrial Cancer, Endometrial NeoplasmNCT06620029BioMimetix JV, LLC27